FRAZIER LIFESCIENCES ACQUISITION CORPORATION

Press Releases Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

Real-time Estimate Tradegate Other stock markets 02:35:01 2024-05-29 am EDT			5-day change	1st Jan Change
17.8 ^EUR	-6.81%		-1.95%	+70.99%

May. 16	Transcript : NewAmsterdam Pharma Company N.V. - Special Call
May. 15	TD Cowen Starts NewAmsterdam Pharma With Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	May. 21	GL
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	May. 21	AQ
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results	May. 09	GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 03	GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 03	AQ
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	May. 02	GL
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	May. 02	AQ
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	Apr. 09	GL
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	Apr. 01	GL
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	Apr. 01	AQ
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress	Mar. 25	GL
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD	Mar. 12	GL
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update	Feb. 28	GL
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update	Feb. 28	AQ
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March	Feb. 26	GL
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March	Feb. 26	AQ
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants	Feb. 13	GL
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants	Feb. 13	AQ
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants	Feb. 13	GL
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants	Feb. 13	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

Press Releases

Filters